Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 19, Issue 3, Pages 169-171Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/14712598.2019.1570498
Keywords
Head and neck cancer; immunological check point inhibitors; nivolumab; cetuximab; pembrolizumab